Vikram Purohit
Stock Analyst at Morgan Stanley
(1.85)
# 3,219
Out of 5,067 analysts
160
Total ratings
34.38%
Success rate
-8.41%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Vikram Purohit
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMPS COMPASS Pathways | Maintains: Overweight | $10 → $11 | $5.18 | +112.36% | 2 | Nov 5, 2025 | |
| ZBIO Zenas BioPharma | Maintains: Overweight | $31 → $34 | $38.25 | -11.11% | 3 | Oct 28, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Overweight | $80 → $79 | $74.00 | +6.76% | 11 | Oct 20, 2025 | |
| ABSI Absci | Maintains: Overweight | $6.4 → $5.89 | $2.96 | +98.99% | 3 | Aug 18, 2025 | |
| RXRX Recursion Pharmaceuticals | Assumes: Equal-Weight | $5 | $4.33 | +15.47% | 4 | Jul 3, 2025 | |
| ASND Ascendis Pharma | Upgrades: Overweight | $180 → $250 | $209.03 | +19.60% | 19 | May 5, 2025 | |
| INCY Incyte | Maintains: Equal-Weight | $69 → $65 | $106.24 | -38.82% | 24 | Mar 24, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Overweight | $125 → $190 | $151.20 | +25.66% | 19 | Feb 27, 2025 | |
| FHTX Foghorn Therapeutics | Maintains: Equal-Weight | $6 → $9 | $4.56 | +97.37% | 9 | Sep 24, 2024 | |
| GMAB Genmab | Maintains: Equal-Weight | $31 | $30.82 | +0.58% | 2 | Sep 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $16 | $125.71 | -87.27% | 2 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $10 | $30.76 | -67.49% | 8 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $46 → $6 | $9.95 | -39.70% | 1 | Nov 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $43 → $42 | $12.23 | +243.42% | 8 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $38 → $41 | $65.59 | -37.49% | 12 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $120 → $40 | $11.83 | +238.12% | 7 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $13 | $2.14 | +507.48% | 1 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $39 → $38 | $17.11 | +122.09% | 6 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $24 → $20 | $8.86 | +125.73% | 5 | Aug 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $11 → $10 | $18.50 | -45.95% | 11 | Jul 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $0.99 | +2,121.77% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $40 → $20 | $13.38 | +49.48% | 2 | Aug 5, 2020 |
COMPASS Pathways
Nov 5, 2025
Maintains: Overweight
Price Target: $10 → $11
Current: $5.18
Upside: +112.36%
Zenas BioPharma
Oct 28, 2025
Maintains: Overweight
Price Target: $31 → $34
Current: $38.25
Upside: -11.11%
Halozyme Therapeutics
Oct 20, 2025
Maintains: Overweight
Price Target: $80 → $79
Current: $74.00
Upside: +6.76%
Absci
Aug 18, 2025
Maintains: Overweight
Price Target: $6.4 → $5.89
Current: $2.96
Upside: +98.99%
Recursion Pharmaceuticals
Jul 3, 2025
Assumes: Equal-Weight
Price Target: $5
Current: $4.33
Upside: +15.47%
Ascendis Pharma
May 5, 2025
Upgrades: Overweight
Price Target: $180 → $250
Current: $209.03
Upside: +19.60%
Incyte
Mar 24, 2025
Maintains: Equal-Weight
Price Target: $69 → $65
Current: $106.24
Upside: -38.82%
Axsome Therapeutics
Feb 27, 2025
Maintains: Overweight
Price Target: $125 → $190
Current: $151.20
Upside: +25.66%
Foghorn Therapeutics
Sep 24, 2024
Maintains: Equal-Weight
Price Target: $6 → $9
Current: $4.56
Upside: +97.37%
Genmab
Sep 11, 2024
Maintains: Equal-Weight
Price Target: $31
Current: $30.82
Upside: +0.58%
Apr 11, 2024
Maintains: Equal-Weight
Price Target: $15 → $16
Current: $125.71
Upside: -87.27%
Nov 13, 2023
Maintains: Overweight
Price Target: $45 → $10
Current: $30.76
Upside: -67.49%
Nov 7, 2023
Downgrades: Equal-Weight
Price Target: $46 → $6
Current: $9.95
Upside: -39.70%
Aug 29, 2023
Maintains: Overweight
Price Target: $43 → $42
Current: $12.23
Upside: +243.42%
Dec 19, 2022
Maintains: Equal-Weight
Price Target: $38 → $41
Current: $65.59
Upside: -37.49%
Dec 12, 2022
Maintains: Equal-Weight
Price Target: $120 → $40
Current: $11.83
Upside: +238.12%
Nov 10, 2022
Initiates: Equal-Weight
Price Target: $13
Current: $2.14
Upside: +507.48%
Nov 4, 2022
Maintains: Equal-Weight
Price Target: $39 → $38
Current: $17.11
Upside: +122.09%
Aug 24, 2022
Maintains: Equal-Weight
Price Target: $24 → $20
Current: $8.86
Upside: +125.73%
Jul 25, 2022
Maintains: Underweight
Price Target: $11 → $10
Current: $18.50
Upside: -45.95%
Aug 10, 2021
Initiates: Overweight
Price Target: $22
Current: $0.99
Upside: +2,121.77%
Aug 5, 2020
Maintains: Equal-Weight
Price Target: $40 → $20
Current: $13.38
Upside: +49.48%